The administration of estrogens to man produces sustained elevation above normal levels of plasma (1, 2). The elevated levels of plasma 17-OHCS are associated with an augmented response of plasma levels of these steroids to exogenous adrenocorticotropic hormone (ACTH) and with a marked delay in the rate of clearance of exogenous cortisol from plasma (2). The last trimester of pregnancy is associated with similar changes in levels of plasma 17-OHCS and in their response to exogenous ACTH (3-9). In the last trimester of pregnancy there is a variable increase in urinary 17-OHCS excretion, a decrease in the rate of clearance of exogenous cortisol from plasma (9-11), a decrease in the rate of clearance of exogenous tetrahydrocortisone from plasma (11) and an increase in corticosteroid-binding protein (12). The apparently normal adrenal status of pregnant women and of patients treated with estrogens for long periods of time suggests that the administration of estrogens to man elevates plasma 17-OHCS levels by altering the normal metabolism of endogenous cortisol by a mechanism similar to that seen in pregnancy. Studies have been made of urinary 17-OHCS excretion, of clearance of tetrahydrocortisone from plasma, and of plasma corticosteroid-binding protein after the administration of estrogens to man.
The administration of estrogens to man produces sustained elevation above normal levels of plasma 17-hydroxycorticosteroids (17-OHCS) (1, 2) . The elevated levels of plasma 17-OHCS are associated with an augmented response of plasma levels of these steroids to exogenous adrenocorticotropic hormone (ACTH) and with a marked delay in the rate of clearance of exogenous cortisol from plasma (2) . The last trimester of pregnancy is associated with similar changes in levels of plasma 17-OHCS and in their response to exogenous ACTH (3) (4) (5) (6) (7) (8) (9) . In the last trimester of pregnancy there is a variable increase in urinary 17-OHCS excretion, a decrease in the rate of clearance of exogenous cortisol from plasma (9) (10) (11) , a decrease in the rate of clearance of exogenous tetrahydrocortisone from plasma (11) and an increase in corticosteroid-binding protein (12) . The apparently normal adrenal status of pregnant women and of patients treated with estrogens for long periods of time suggests that the administration of estrogens to man elevates plasma 17-OHCS levels by altering the normal metabolism of endogenous cortisol by a mechanism similar to that seen in pregnancy. Studies have been made of urinary 17-OHCS excretion, of clearance of tetrahydrocortisone from plasma, and of plasma corticosteroid-binding protein after the administration of estrogens to man.
MATERIALS AND METHODS
The patients studied were primarily adult females ranging in age from 37 to 75 years, all of whom either had been surgically castrated or were at least 3 years past a spontaneous menopause. A number of these subjects were patients with metastatic carcinoma of the * This work was supported in part by a research grant from The National Cancer Institute, Bethesda, Md. breast. One male was studied during recovery from a myocardial infarction.
After appropriate control studies, the patients were treated for periods of 2 weeks to 6 months with either oral ethinyl estradiol (Estinyl), diethylstilbestrol or conjugated equine estrogens (Premarin). Only doses of these preparations which uniformly elevated plasma 17-OHCS levels above normal were used in the studies (Table I) (15) . The clearance from plasma of exogenous tetrahydrocortisone was studied in 7 patients in whom plasma 17-OHCS levels had been elevated by estrogen therapy and in 4 control subjects. Seventy-five mg of crystalline tetrahydrocortisone was dissolved in 7 to 8 ml of hot alcohol, added to 80 to 100 ml of normal saline and administered intravenously over a period of 2 to 5 minutes. Plasma samples were obtained prior to and at approximately 20, 40, 60 and 90 minutes after each infusion. Plasma 17-OHCS were determined by the method of Peterson and colleagues (15) .
The binding of cortisol to a corticosteroid-binding globulin, transcortin, was kindly determined by Drs. Sandberg and Slaunwhite by the method which they have described (12, 16) . Binding was determined by dialyzing 10 ml of diluted plasma (1: 5 with physiological saline) against 30 ml of saline, containing approximately 0.3 ,sg of C14 cortisol at 4°C. Binding was also determined by the addition of 1 1Ag of cortisol to the saline in order to measure the decrease in the binding caused by the addition of cortisol-"transcortin capacity." The binding capacity is inversely related to the decrease in binding caused by the addition of 1 Ag of cortisol. Plasma 17-OHCS levels, transcortin-binding and transcortin capacity were measured in 12 patients, 6 of whom previously have been reported (16) , before and at 2 to 3 day intervals after the institution of therapy. RESULTS 1. Effect of oral ethinyl estradiol (0.5 mg per day) upon urinary excretion of steroids. Ethinyl estradiol administration for periods of 2 to 4 weeks resulted in a significant decrease (p < 0.01) in the mean excretion of total urinary 17-hydroxycorticosteroids in nine patients studied (Table II) . Since the excretion of free urinary 17-OHCS was not significantly altered by the administration of estrogens, the major decrease in urinary 17-OHCS appeared to be in the conjugated fraction. (20) .
If cortisol bound to corticosteroid-binding protein is physiologically "inactive" and less available for metabolic disposal than is unbound corti- The quantitatively exaggerated rise in levels of 17-OHCS after corticotropin may be explained, at least in part, by the delay in clearance of cortisol from plasma. The delayed plasma clearance of cortisol is presumably due to the decreased availability of the transcortin-bound fraction of cortisol for metabolism and conjugation by the liver. The decrease in conjugated urinary 17-OHCS may also be explained by such a sequence of events. The unchanged levels of free cortisol in the urine found in this study are compatible with the clinically normal adrenal state of patients receiving estrogens.
The delayed clearance of exogenous tetrahydrocortisone, a steroid not bound in any significant degree by corticosteroid-binding globulin (18) , cannot be explained by increases in the binding capacity of this protein. The existence of a protein-binding system for tetrahydrocortisone, as yet undescribed, which may be influenced by the administration of estrogens, should be considered. There is evidence for a diversity of protein-binding systems affected by estrogens in the reported increases in thyroid-binding globulin induced by the administration of diethylstilbestrol (21) .
The similarity in changes produced by adequate doses of estrogens and those that occur spontaneously in pregnancy is striking. All of the alterations in steroid metabolism induced by administration of estrogens, except for the decrease in conjugated urinary corticosteroids, occur in the last trimester of pregnancy. The exact physiological significance of the altered corticosteroid metabolism during pregnancy and estrogen administration remains to be defined. Although many of the changes in steroid metabolism noted in both situations can be adequately explained by increases in corticosteroid-binding protein, the data do not exclude the possibility of other contributing mechanisms.
SUMMARY
Estrogen administration to man in adequate dosage produces:
1. Elevation above normal of plasma 17-hydroxycorticosteroid (17-OHCS) levels and excessive rise of these steroids after intravenous ACTH without clinical hyperadrenocorticism.
2. Decreased urinary excretion of conjugated 17-OHCS.
3. Delay in rate of clearance from plasma of exogenous cortisol and tetrahydrocortisone.
4. Increase in cortisol-binding to corticosteroidbinding proteins (transcortin) and in transcortinbinding capacity. This mechanism can explain the reported findings, excepting the diminished rate of clearance from plasma of exogenous tetrahydrocortisone which remains unexplained by the data reported.
